Compounds > maytansinol
Page last updated: 2024-11-13

maytansinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID117590640
MeSH IDM0562529

Synonyms (4)

Synonym
maytansinol ,
57103-68-1
AC-27769
AKOS025401987

Research Excerpts

Overview

inol. Maytansinol is a valuable precursor for the preparation of maytansine derivatives (known as mayTansinoids)

ExcerptReferenceRelevance
"Maytansinol is a valuable precursor for the preparation of maytansine derivatives (known as maytansinoids). "( Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders.
Abel, AC; Altmann, KH; Álvarez-Bernad, B; Boiarska, Z; Díaz, JF; Lucena-Agell, D; Marzullo, P; Passarella, D; Pérez-Peña, H; Pieraccini, S; Prota, AE; Sironi, M; Vasile, F, 2022)		3.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (44.44)24.3611
2020's4 (44.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.70 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
maytansine
Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.		3.790alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound		antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator
monomethyl auristatin e
[no description available]		2.1110
monomethylauristatin f
monomethylauristatin F: structure in first source		2.1110
ansamitocins
ansamitocins: maytansinoid antibiotics produced by an actinomycete strain Norcardia sp. No. C-15003 (N-1); P-1 & P-2 identified with maytanacine & maytansinol propionate, respectively; structures for ansamitocins P-0, P-1, P-2, P-3, P-3', P-4 in second source		2.1310
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.5420
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.5420
Complication, Postoperative
[description not available]		02.1110
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		02.1110
Carcinoma, Non-Small Cell Lung
[description not available]		02.1310
Cancer of Lung
[description not available]		02.1310
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.1310
Lung Neoplasms
Tumors or cancer of the LUNG.		02.1310
Experimental Leukemia
[description not available]		01.9510
Experimental Neoplasms
[description not available]		01.9510